Incredible new episode with Doug O'Laughlin of @fabknowledge and @SemiAnalysis_!!
On how the semi industry is leading AI forward, the winners of the AI race, an intriguing investment opp in the newest bottleneck for the industry & the deep recession in the non-AI semi world.
.@ElliotTurn and @mihaljevic welcome Doug O'Laughlin of SemiAnalysis and Fabricated Knowledge. Doug shares insights into semiconductors, how the industry leads AI forward, AI winners, opportunity in an industry bottleneck, and the non-AI semi recession.
https://t.co/jtmhlDynqj
Only 24% of S&P 500 members outperforming the index over the past 3 months ... going back to the 1970s, there are only a handful of other periods with lower %s.
@NDR_Research | past performance is no guarantee of future results
People don't like the 1999 comparison bc we don't have enough big caps with triple digit PEs, but IMO this is where it's most on point.
Everything not AI is sold to buy more AI every day the market is open.
So, again, this is just shouting into a void.
But this is the most new lows within the S&P 500 $SPY on a day the index poked above a prior all-time closing high.
Ever.
Like EVER, ever.
"GS High Beta Momentum Pair is having its biggest 1-d move higher in 5+ yrs today …up 866 bps today (laggards down 2-3%, leaders up 5-6%) ..zooming out, the $QQQ is now up 28% since the 3/30 close with only one day of anything larger than a 57 bps daily pullback along the way"
@JustinRTipton@systvest Your premise is false. With how you phrase it, no stock would ever move when shares change hands. The enthusiasm & urgency of the buyers and sellers on both sides could not be more different.
So, again, this is just shouting into a void.
But this is the most new lows within the S&P 500 $SPY on a day the index poked above a prior all-time closing high.
Ever.
Like EVER, ever.
Great episode with @peter_mantas covering turmoil at the FDA & it's impact on biotech & life science!
It's not every day that you schedule a guest in advance and end up with an incredibly timely headline right before recording. Learn how Makary's firing impacts investments:
New episode: @ElliotTurn and @mihaljevic chat with @Peter_Mantas about the FDA shakeup and what it means for gene therapy approvals, the $QURE saga, AI and drug discovery, and valuing biotech "picks and shovels" companies like $CLPT and $RGEN. Don't miss this biotech masterclass.
New episode: @ElliotTurn and @mihaljevic chat with @Peter_Mantas about the FDA shakeup and what it means for gene therapy approvals, the $QURE saga, AI and drug discovery, and valuing biotech "picks and shovels" companies like $CLPT and $RGEN. Don't miss this biotech masterclass.
@mihaljevic I think that has to be parsed with nuance. The hyperscalers are investing ahead of revenue, growing at unprecedented rates for the scale, with great incremental margins.
The suppliers who are benefiting from these bottlenecks in the build out are overearning.
@John_Hempton@adamfeuerstein@DmitryKovalchuk It's a platform--they are proving that the process works in 1 indication and can do this for other genetic causes of hearing losses. DBTX pursued the fastest route to market.
Someone should ask @DrMakaryFDA and @NIHDirector_Jay about this directly. They want you to believe there wasn't malicious intent behind de-funding what could be a profound breakthrough in cancer to settle political scores.
That is literally a lie, as Bhattacharya wrote an op-ed trying to explain their move. He essentially was arguing that the "brand" of mRNA is tainted by public backlash to the COVID vaccine.
https://t.co/5KXQJtCCxM
That is literally a lie, as Bhattacharya wrote an op-ed trying to explain their move. He essentially was arguing that the "brand" of mRNA is tainted by public backlash to the COVID vaccine.
https://t.co/5KXQJtCCxM
That is literally a lie, as Bhattacharya wrote an op-ed trying to explain their move. He essentially was arguing that the "brand" of mRNA is tainted by public backlash to the COVID vaccine.
https://t.co/5KXQJtCCxM
I asked FDA Commissioner Marty Makary if the promising new signs about the mRNA-based vaccine for pancreatic cancer made HHS reconsider its decision to cancel half a billion dollars' worth of federal funding for mRNA vaccine projects.
@kaitlancollins That is literally a lie, as Bhattacharya wrote an op-ed trying to explain their move. He essentially was arguing that the "brand" of mRNA is tainted by public backlash to the COVID vaccine. https://t.co/5KXQJtCCxM